ライフサイエンスコーパス: postmenopausal women

1 dence of and mortality by race/ethnicity for postmenopausal women.

2 th an increased risk of bladder cancer among postmenopausal women.

3 ine are not risk factors for hypertension in postmenopausal women.

4 in gallate (EGCG) on blood lipids in healthy postmenopausal women.

5 ted with risk of CRC in this large cohort of postmenopausal women.

6 itable for application in this population of postmenopausal women.

7 LS mortality associated with strenuous PA in postmenopausal women.

8 were inversely associated with T2D in these postmenopausal women.

9 end points in perimenopausal, menopausal, or postmenopausal women.

10 one-receptor-positive early breast cancer in postmenopausal women.

11 to determine the skeletal benefits of SCF in postmenopausal women.

12 servational Study (1993-2012), a US study of postmenopausal women.

13 her risk factors for CTS identified in these postmenopausal women.

14 ism for the increased ovarian cancer risk in postmenopausal women.

15 n on the risk of cancer in a large cohort of postmenopausal women.

16 premenopausal women but an increased risk in postmenopausal women.

17 , non-Hodgkin lymphoma, and breast cancer in postmenopausal women.

18 %, for women with no family history, and for postmenopausal women.

19 sion of the gene encoding NKB is elevated in postmenopausal women.

20 riety of cancers, including breast cancer in postmenopausal women.

21 ely capture mortality risk in this sample of postmenopausal women.

22 er, open-label intervention in 14 overweight postmenopausal women.

23 ets could be a risk factor for depression in postmenopausal women.

24 found to be associated with less ACH loss in postmenopausal women.

25 obtain percent of in vivo drug absorption in postmenopausal women.

26 ith increased invasive breast cancer risk in postmenopausal women.

27 rimary preventive measures for depression in postmenopausal women.

28 range, such as serum from men, children, and postmenopausal women.

29 s, and clinical feasibility was evaluated in postmenopausal women.

30 duced risk of breast cancer, particularly in postmenopausal women.

31 to more robustly assess mortality risk among postmenopausal women.

32 consumption on vascular function in healthy postmenopausal women.

33 4 y of MHT on cognition and mood in recently postmenopausal women.

34 sociations of ESH and T2D were based only in postmenopausal women.

35 f vitamin D on calcium absorption in healthy postmenopausal women.

36 development of new contralateral tumours in postmenopausal women.

37 to the diet can contribute to the health of postmenopausal women.

38 rdiovascular disease (CVD), and cancer among postmenopausal women.

39 intake is not detrimental to bone health in postmenopausal women.

40 uces incidence of breast cancer in high-risk postmenopausal women.

41 on group, with profiles similar to those for postmenopausal women.

42 r breast, endometrial, or ovarian cancers in postmenopausal women.

43 ome gene expression in the adipose tissue of postmenopausal women.

44 increases the risk of endometrial cancer in postmenopausal women.

45 periodontitis was not seen in this cohort of postmenopausal women.

46 ial effect on bone turnover markers (BTM) in postmenopausal women.

47 impact of greatest concern in young boys and postmenopausal women.

48 c types of soda, and risk of hip fracture in postmenopausal women.

49 infections, and that M. avium infects mainly postmenopausal women.

50 increased prevalence of breast cancer among postmenopausal women.

51 vention of fractures in noninstitutionalized postmenopausal women.

52 , presented with higher quantitative BE than postmenopausal women.

53 primary prevention of chronic conditions in postmenopausal women.

54 eased breast cancer incidence in a cohort of postmenopausal women.

55 tive as a screening tool for osteoporosis in postmenopausal women.

56 has a negative impact on quality of life of postmenopausal women.

57 itable for application in this population of postmenopausal women.

58 compared with continuous use of letrozole in postmenopausal women.

59 d motivate programs for weight loss in obese postmenopausal women.

60 ciated with increased risk of diabetes among postmenopausal women.

61 opausal women and 61.7 (7.2) years among the postmenopausal women.

62 cancer risk factors among premenopausal and postmenopausal women.

63 women and 54.7% (95% CI, 46.5%-54.7%) among postmenopausal women.

64 nondairy, and vegetable origins) in healthy postmenopausal women.

65 higher compared to 13.8 +/- 11.8 pmol/L for postmenopausal women.

66 Among postmenopausal women, 22.8% (95% CI, 18.3%-27.3%) of bre

67 Participants included 58 postmenopausal women: 29 with BCa on AIs and 29 controls

68 ndomised controlled trial, premenopausal and postmenopausal women 35-70 years of age deemed to be at

69 e concentrations were measured in 80 men and postmenopausal women (48 men, 32 women, age 40-65 y) enr

70 eding trial that was conducted in 81 men and postmenopausal women [49 men and 32 women; age range: 40

71 A total of 155,069 postmenopausal women, 50-79 years of age, who were enrol

72 A total of 2303 healthy postmenopausal women 55 years or older were randomized,

73 of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low

74 In previously inactive postmenopausal women, a 1-year prescription of moderate

75 onsuming a Western-style diet, 49 men and 32 postmenopausal women [age range: 40-65 y, body mass inde

76 ion, and invasive breast cancer among 12,701 postmenopausal women aged >/=50 years in a Women's Healt

77 Postmenopausal women aged 18 years or older with histolo

78 Postmenopausal women aged 18 years or older with histolo

79 cebo-controlled, phase 2 study, we recruited postmenopausal women aged 18 years or older with oestrog

80 Feb 2, 2003, and Jan 31, 2012, we recruited postmenopausal women aged 40-70 years from 18 countries

81 Observational follow-up of US multiethnic postmenopausal women aged 50 to 79 years enrolled in 2 r

82 MetS and periodontitis were examined in 657 postmenopausal women aged 50 to 79 years enrolled in a p

83 A total of 27,347 postmenopausal women aged 50 to 79 years were enrolled a

84 is randomised controlled trial, we recruited postmenopausal women aged 50-74 years from 13 centres in

85 fication Trial.Participants comprised 48,835 postmenopausal women aged 50-79 y; 40% were randomly ass

86 A total of 67,130 postmenopausal women aged 50-79 years were followed for

87 t of Women's Health Initiative participants (postmenopausal women aged 50-79 years) enrolled between

88 on microsimulation model of osteoporosis for postmenopausal women aged 55 years or older was develope

89 , placebo-controlled, phase 3 FREEDOM trial, postmenopausal women aged 60-90 years with osteoporosis

90 n's Health Initiative (WHI) enrolled 161 809 postmenopausal women, aged 50 to 79 years (mean [SD] age

91 e mortality, and other major endpoints among postmenopausal women, aged 50-79 years at HT initiation.

92 djudicated breast cancer end points in 67142 postmenopausal women ages 50 to 79 years at 40 US clinic

93 nd 18.4%, 12.7%, and 10.5%, respectively, in postmenopausal women.An interactive program for calculat

94 s severity was 1.4 (0.9, 2.1) (P = 0.17) for postmenopausal women and 1.6 (1.0, 2.5) (P = 0.03) for m

95 METHODS AND Data of 1023 postmenopausal women and 1124 men (>/=45 years) with car

96 BC count was measured at baseline in 160,117 postmenopausal women and again in year 3 in 74,375 parti

97 alent risk factor for both premenopausal and postmenopausal women and had the largest effect on the P

98 ctive strategy for osteoporosis screening in postmenopausal women and has the potential to prevent a

99 In contrast, postmenopausal women and men showed consistently low lev

100 onsidered global health issues that threaten postmenopausal women and the older population.

101 for the prevention of chronic conditions in postmenopausal women and whether outcomes vary among wom

102 tion is associated with lower rates of HF in postmenopausal women and whether the effects differ betw

103 baseline hemoglobin was measured in 160,081 postmenopausal women and year 3 hemoglobin was measured

104 ian cancer incidence is highest in peri- and postmenopausal women, and epidemiological studies have e

105 es of unmedicated naturally ovulating women, postmenopausal women, and men daily and determined urina

106 increased risk for cardiovascular events in postmenopausal women, and that this association is stron

107 own whether similar risks exist for recently postmenopausal women, and whether MHT affects mood in yo

108 cholesterol-lowering medications.CVD risk in postmenopausal women appears to be sensitive to a change

109 For postmenopausal women, aromatase inhibitors (AIs) are the

110 he present study, self-reported intakes from postmenopausal women at 40 participating US clinical cen

111 ovides support for the use of anastrozole in postmenopausal women at high risk of breast cancer.

112 romatase inhibitors prevent breast cancer in postmenopausal women at high risk of the disease but are

113 -blind IBIS-II trial recruited 3864 healthy, postmenopausal women at increased risk of breast cancer

114 e-specific and health-related QOL in healthy postmenopausal women at risk for breast cancer.

115 , we collected repeat blood samples from 119 postmenopausal women (average age = 59.4 (standard devia

116 tive recruited a large prospective cohort of postmenopausal women between 1993 and 1998.

117 In this large prospective cohort of postmenopausal women, bisphosphonate use was associated

118 A total of 439 overweight/obese, healthy, postmenopausal women [body mass index (BMI) > 25 kg/m(2)

119 In postmenopausal women, body fat is a major source of estr

120 for osteoporosis and reduce fracture risk in postmenopausal women by up to 50%.

121 range of potential nutritional biomarkers in postmenopausal women by using a controlled feeding study

122 associations were particularly strong among postmenopausal women [ (CI: 0.57, 0.93) and (CI: 0.74, 0

123 Overall, men, premenopausal, and postmenopausal women composed 35.1%, 28.4%, and 36.5% of

124 In this secondary analysis of node-negative postmenopausal women, conducted in the era before mammog

125 These results suggest that postmenopausal women consuming a diet in line with a pri

126 tary pattern on the cardiovascular health of postmenopausal women continues to be of public health in

127 cent to the fracture site were obtained from postmenopausal women during fracture repair surgery (fra

128 Study, a longitudinal, prospective cohort of postmenopausal women enrolled from 1993 to 1998 with 8 y

129 th a total of 58146 premenopausal and 144600 postmenopausal women enrolled in the study.

130 Postmenopausal women enrolled in the Women's Health Init

131 We prospectively examined a cohort of 93,676 postmenopausal women enrolled in the Women's Health Init

132 Among postmenopausal women, estrogen-progestin hormone use was

133 and HFrEF in a multiracial cohort of 42 170 postmenopausal women followed up for a mean of 13.2 year

134 h 3, 2003, and Feb 8, 2012, we enrolled 2980 postmenopausal women from 236 centres in 14 countries an

135 tions among serum E2, HT use, and ACH in 613 postmenopausal women from the Buffalo OsteoPerio study.

136 ast cancer cases were diagnosed among 57,403 postmenopausal women from the E3N prospective cohort dur

137 years of follow-up in more than 96,000 white postmenopausal women from the Nurses' Health Study and m

138 An analysis was conducted in postmenopausal women from the Nurses' Health Study cohor

139 The study population comprised 51,754 postmenopausal women from the Women's Health Initiative

140 (CaD) and fracture risk.Data from 5823 white postmenopausal women from the Women's Health Initiative

141 alized controlled feeding study in which 153 postmenopausal women from the Women's Health Initiative

142 Postmenopausal women from the Women's Health Initiative

143 However, among postmenopausal women, greater adherence to HEI-2010 (qua

144 In women with benign tissue, postmenopausal women had a higher PUFA (0.35 +/- 0.06 vs

145 is compared to women before menopause, while postmenopausal women have a similar severity of liver fi

146 atherosclerosis and myocardial infarction in postmenopausal women have been linked to inflammation an

147 Postmenopausal women have increased rates of fibrosis co

148 Cross-sectionally, highly stressed postmenopausal women have shorter telomeres, but only if

149 Among postmenopausal women, hormone therapy with CEE plus MPA

150 iated with increased risk of hip fracture in postmenopausal women; however, a clear mechanism was not

151 ide (TMAO)] and colorectal cancer risk among postmenopausal women in a case-control study nested with

152 on, insulin, and C-reactive protein (CRP) in postmenopausal women in a weight-loss intervention.

153 2000) to follow-up (2002 to 2005) among 655 postmenopausal women in a Women's Health Initiative Obse

154 ent bladder cancers among a cohort of 34,708 postmenopausal women in Iowa (1986-2010).

155 king water and diet and bladder cancer among postmenopausal women in Iowa.

156 d with a modestly increased risk of FI among postmenopausal women in the Nurses' Health Study.

157 A total of 1 312 051 postmenopausal women in the UK Million Women Study, aged

158 Postmenopausal women in the United States, aged 50 to 79

159 use of combined hormone therapy (cHT) among postmenopausal women in the United States.

160 blood pressure and incident hypertension in postmenopausal women in the Women's Health Initiative Ob

161 e study was a prospective analysis in 87,602 postmenopausal women in the Women's Health Initiative Ob

162 acid fractions in breast adipose tissue for postmenopausal women in whom BMI values are not correlat

163 Of 74,750 postmenopausal women included in the study, 3,612 develo

164 reduce the risk of incident kidney stones in postmenopausal women independent of caloric intake and B

165 in a very homogeneous population of healthy postmenopausal women, indicate that there is a beneficia

166 Conclusion Intentional weight loss in postmenopausal women is associated with a lower endometr

167 Estrogen-alone therapy in postmenopausal women is associated with a small but sign

168 one therapy to prevent chronic conditions in postmenopausal women is associated with some benefits, t

169 ular GFJ consumption by middle-aged, healthy postmenopausal women is beneficial for arterial stiffnes

170 of weight loss on endometrial cancer risk in postmenopausal women is limited.

171 benefits and the harms of hormone therapy in postmenopausal women is small to moderate.

172 vidence that isoflavones reduce bone loss in postmenopausal women is unimpressive.

173 findings of higher E2 levels in men than in postmenopausal women may suggest that decreased oestroge

174 iew board-approved study was performed in 40 postmenopausal women (mean age, 63 years; range, 49-78 y

175 tion between MHT and risk of FI among 55,828 postmenopausal women (mean age, 73 years) who participat

176 Among 65,630 postmenopausal women (mean follow-up: 10.8 years), 301 e

177 nd slightly obese individuals (30 men and 22 postmenopausal women, mean +/- SD age: 62 +/- 6 y) were

178 KEEPS-Cog findings suggest that for recently postmenopausal women, MHT did not alter cognition as hyp

179 Results For postmenopausal women, MUFA was lower (0.38 +/- 0.06 vs 0

180 cases of invasive breast cancer developed in postmenopausal women (n = 121,700) in the Nurses' Health

181 performed in subcutaneous adipose tissue of postmenopausal women (n = 26 after LG, n = 31 after HG).

182 Patients and Methods Postmenopausal women (N = 36,794) ages 50 to 79 years at

183 Postmenopausal women (N = 913) who were participants of

184 om these pathways in a case-control study of postmenopausal women nested within the Women's Health In

185 arger for biennial vs annual screeners among postmenopausal women not taking HT (eg, any characterist

186 Postmenopausal women not using HT who are diagnosed as h

187 In this multiracial cohort of postmenopausal women, obesity stands out as a significan

188 Conclusion In our observational cohort of postmenopausal women observed from 2004 to 2011, BP use,

189 We enrolled postmenopausal women of any age with hormone receptor-po

190 attern was associated with increased risk in postmenopausal women only (HR for high compared with low

191 with body weight (P < .01) but decreased in postmenopausal women (P < .01).

192 (95% CI: 0.91, 1.09) based on 1,172 cases in postmenopausal women; p-interaction=0.08].

193 Data of 3,117 postmenopausal women participants of the Rotterdam Study

194 Methods The study population included 64,438 postmenopausal women participating in the French E3N (Et

195 ndometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI.

196 orectomy (BSO), and incidence of diabetes in postmenopausal women participating in the Women's Health

197 should be performed in men aged >/=50 years, postmenopausal women, patients with a history of fragili

198 n (YM), young women (YW), older men (OM) and postmenopausal women (PMW); and (2) measured changes in

199 e breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25

200 nd risk of colorectal cancer (CRC) in 87,042 postmenopausal women recruited from 1993-1998 by the Wom

201 ongitudinal prospective cohort evaluation of postmenopausal women recruited from 40 clinical centers.

202 ate, are effective bone-preserving agents in postmenopausal women regardless of their equol-producing

203 group analyses revealed that high-performing postmenopausal women (relative to low and middle perform

204 d 96.7 mg/L in men, premenopausal women, and postmenopausal women, respectively.

205 In postmenopausal women, serum PFOS was negatively associat

206 The study that involved postmenopausal women showed a wide range of porosity ind

207 Postmenopausal women showed enhanced bilateral hippocamp

208 The relative preponderance among postmenopausal women suggests that estrogen deprivation

209 earing in premenopausal women and obesity in postmenopausal women suggests that this relationship cou

210 With this strategy, 12.8% of postmenopausal women sustained hip fractures in their re

211 In contrast, among postmenopausal women, TCDD levels were associated with e

212 In postmenopausal women, the corresponding difference in ra

213 le-blinded trial was performed in 14 healthy postmenopausal women to compare doses of 0, 10, and 20 g

214 iated with serious adverse health effects in postmenopausal women, use of menopausal hormone therapy

215 In estrogen-deficient, postmenopausal women, vitamin D and calcium deficiency i

216 CI of 2-year increments) with depression in postmenopausal women was shown for increasing age at men

217 bone mineral density (BMD) loss in peri- and postmenopausal women.We systematically searched EMBASE a

218 Men and postmenopausal women were also scanned after pretreatmen

219 Seventy-six healthy postmenopausal women were randomly assigned to placebo o

220 A total of 643 healthy postmenopausal women were stratified according to time s

221 1410 (36%) postmenopausal women were then enrolled in a bone substu

222 e HRT decreases the risk of breast cancer in postmenopausal women, whereas combined estrogen plus a p

223 ficantly increased bone calcium retention in postmenopausal women, which improved the bone calcium ba

224 astrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease

225 l health and evaluate salivary biomarkers in postmenopausal women who are survivors of early-stage (I

226 ed by the sharp increase in HCC incidence in postmenopausal women who do not take hormone replacement

227 Participants were premenopausal and postmenopausal women who had been diagnosed with epithel

228 and 3 months) biopsies were obtained from 89 postmenopausal women who had estrogen receptor-alpha pos

229 Treatment is generally recommended in postmenopausal women who have a bone mineral density T s

230 primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy.

231 ry prevention of chronic conditions for most postmenopausal women who have had a hysterectomy.

232 d using primary breast tumor samples from 50 postmenopausal women who later developed metastatic brea

233 ose, starch, carbohydrate) and depression in postmenopausal women who participated in the Women's Hea

234 lth Initiative RA Study (1993-2010), sampled postmenopausal women who reported RA at baseline (1993-1

235 vascular disease, cancer, and diabetes among postmenopausal women who were enrolled in the Women's He

236 blood pressures at annual visit 3 in 29,985 postmenopausal women who were not hypertensive at baseli

237 The odds of choroidal nevus in postmenopausal women who were overweight and obese were

238 ndomized, crossover intervention trial in 24 postmenopausal women who were prescreened for their abil

239 Data from 488 postmenopausal women with (1) histologic diagnosis of no

240 Postmenopausal women with (n = 22) and without (n = 22)

241 The study enrolled postmenopausal women with a diagnosis of MBC and prior e

242 n this open-label, randomised phase 2 study, postmenopausal women with advanced oestrogen receptor-po

243 The Task Force concluded that postmenopausal women with an estimated 5-year risk for b

244 ry prevention of chronic conditions for most postmenopausal women with an intact uterus and that estr

245 Participants were 400 inactive postmenopausal women with body mass index 22 to 40, dise

246 and Participants: A retrospective cohort of postmenopausal women with breast cancer diagnosed from J

247 4747 (89.8%) premenopausal and 12502 (95.1%) postmenopausal women with breast cancer had at least 1 b

248 ar reduces the risk of clinical fractures in postmenopausal women with breast cancer receiving aromat

249 arotid plaque composition in elderly men and postmenopausal women with carotid atherosclerosis, as we

250 KD or were receiving dialysis (3 trials), or postmenopausal women with CKD (4 trials).

251 Participants were postmenopausal women with clinically detected node-negat

252 l to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ under

253 In MA.27, postmenopausal women with early stage hormone (oestrogen

254 e-blind, phase III trial included AI-treated postmenopausal women with early-stage breast cancer and

255 -blind trial, BIG 1-98, which enrolled 8,010 postmenopausal women with early-stage, hormone receptor-

256 bined with endocrine therapy is effective in postmenopausal women with endocrine-resistant, hormone r

257 s and surgical samples were obtained from 14 postmenopausal women with estrogen receptor-positive (ER

258 Postmenopausal women with estrogen receptor-positive, lo

259 We used multimodal imaging to compare 26 postmenopausal women with fibromyalgia with 25 healthy c

260 A total of 13273 postmenopausal women with hormone receptor-positive brea

261 INTERPRETATION: In postmenopausal women with hormone receptor-positive brea

262 ble-blind trial that randomly assigned 6,193 postmenopausal women with hormone receptor-positive earl

263 and tissue samples were obtained from 2,137 postmenopausal women with hormone receptor-positive earl

264 Postmenopausal women with hormone-positive ductal carcin

265 Postmenopausal women with hormone-positive ductal carcin

266 After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive adva

267 ves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive brea

268 strozole offers another treatment option for postmenopausal women with hormone-receptor-positive DCIS

269 acy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS

270 than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive inva

271 Methods Postmenopausal women with HR-positive and node-positive

272 ase 3 clinical trial (NCT00073528), in which postmenopausal women with HR-positive invasive breast ca

273 th letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative rec

274 redictor has the potential to identify those postmenopausal women with locally advanced, estrogen-rec

275 In postmenopausal women with low bone mass, romosozumab was

276 ity of these findings is limited to recently postmenopausal women with low cardiovascular risk profil

277 limus may be administered with exemestane to postmenopausal women with MBC whose disease progresses w

278 this randomized, open-label phase II trial, postmenopausal women with newly diagnosed operable estro

279 to hormone therapy (n = 26) and asymptomatic postmenopausal women with no history of depression (n =

280 menopausal state confers fibrosis risk among postmenopausal women with nonalcoholic fatty liver disea

281 ime from menopause with fibrosis severity in postmenopausal women with nonalcoholic fatty liver disea

282 Postmenopausal women with nonalcoholic steatohepatitis a

283 weight and obese were 2 times higher than in postmenopausal women with normal body mass index (OR, 2.

284 d Methods The trial randomly assigned 48,835 postmenopausal women with normal mammograms and without

285 lpha-OH), and stimulated equol production in postmenopausal women with osteopenia.

286 We enrolled 4093 postmenopausal women with osteoporosis and a fragility f

287 In postmenopausal women with osteoporosis who were at high

288 b, which is widely used for the treatment of postmenopausal women with osteoporosis.

289 Participants included asymptomatic postmenopausal women with past PMD responsive to hormone

290 t MUC1 had 2.5 times stronger association in postmenopausal women with progestin use (beta=-0.028, p=

291 Postmenopausal women with six or more nevi had a 45.5% h

292 ncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II or III ER-positive (A

293 Ninety-two postmenopausal women with stage II to IIIA primary breas

294 The disease typically presents in postmenopausal women, with a few months of abdominal pai

295 bacterial disease (PNTM) often affects white postmenopausal women, with a tall and lean body habitus

296 endent of leisure-time physical activity, in postmenopausal women without a history of CVD.

297 rovide independent prognostic information in postmenopausal women without diabetes mellitus.

298 all cohort, however, it was beneficial among postmenopausal women without major HF precursors while o

299 number of cutaneous nevi among a subgroup of postmenopausal women without postmenopausal hormone use

300 This cohort (n = 101,504) included postmenopausal women without T2D who completed a baselin